Heparin as a therapy for COVID-19: current evidence and future possibilities
- 1 August 2020
- journal article
- review article
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 319 (2), L211-L217
- https://doi.org/10.1152/ajplung.00199.2020
Abstract
Coronavirus disease 2019 (COVID-19), the clinical syndrome associated with infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). has impacted nearly every country in the world. Despite an unprecedented focus of scientific investigation, there is a paucity of evidence-based pharmacothcrapies against this disease. Because of this lack of data-driven treatment strategies, broad variations in practice patterns have emerged. Observed hypercoagulability in patients with COVID-19 has created debate within the critical care community on the therapeutic utility of heparin. We seek to provide an overview of the data supporting the therapeutic use of heparin, both unfractionated and low molecular weight, as an anticoagulant for the treatment of SARS-CoV-2 infection. Additionally. we review preclinical evidence establishing biological plausibility for heparin and synthetic heparin-like drugs as therapies for COVID-19 through antiviral and anti-inflammatory effects. Finally, we discuss known adverse effects and theoretical off-target effects that may temper enthusiasm for the adoption of heparin as a therapy in COVID-19 without confirmatory prospective randomized controlled trials. Despite previous failures of anticoagulants in critical illness, plausibility of heparin for COVID-19 is sufficiently robust to justify urgent randomized controlled trials to determine the safety and effectiveness of this therapy.Keywords
Funding Information
- NIH HHS (F31 HL143873)
This publication has 51 references indexed in Scilit:
- Low levels of tissue factor lead to alveolar haemorrhage, potentiating murine acute lung injury and oxidative stressThorax, 2012
- Drotrecogin Alfa (Activated) in Adults with Septic ShockNew England Journal of Medicine, 2012
- Inhibition of SARS Pseudovirus Cell Entry by Lactoferrin Binding to Heparan Sulfate ProteoglycansPLOS ONE, 2011
- Venous thromboembolism in critically ill patientsThrombosis and Haemostasis, 2009
- The anti-inflammatory effects of heparin and related compoundsThrombosis Research, 2008
- Augmentation of chemokine production by severe acute respiratory syndrome coronavirus 3a/X1 and 7a/X4 proteins through NF‐κB activationFEBS Letters, 2006
- Viral and Cellular Determinants of the Hepatitis C Virus Envelope-Heparan SulfateInteractionJournal of Virology, 2006
- Burden of Illness in venous ThromboEmbolism in Critical care: a multicenter observational studyJournal of Critical Care, 2005
- Effects of heparin in experimental models of acute pancreatitis and post-ERCP pancreatitisSurgery, 2004
- Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisNew England Journal of Medicine, 2001